Financials in USD. Standardized financial statements.
A compact view of how Fresh Tracks Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $8.01M | $6.94M | $404,000 | $1.82M | $7.92M | $1.62M | $13.82M | $14.53M | $20.95M | $15.22M |
| Revenue Growth? | +15.3% | +1618.6% | -77.8% | -77.0% | +388.1% | -88.3% | -4.9% | -30.6% | +37.7% | 0.0% |
| Cost of Revenue? | $0 | $14.04M | $28.23M | $11.22M | $20.21M | $1.44M | $6.48M | $6.29M | $10.93M | $10.82M |
| Gross Profit? | $8.01M | -$7.10M | -$27.83M | -$9.39M | -$12.30M | $186,000 | $7.34M | $8.24M | $10.02M | $4.39M |
| Gross Margin? | +100.0% | -102.3% | -6887.9% | -515.6% | -155.3% | +11.5% | +53.1% | +56.7% | +47.8% | +28.9% |
| Operating Expenses? | $14.37M | $28.48M | $40.65M | $22.80M | $32.38M | $21.27M | $27.20M | $23.71M | $30.35M | $31.84M |
| Operating Income? | -$6.36M | -$21.53M | -$40.24M | -$20.98M | -$24.47M | -$19.65M | -$13.39M | -$9.18M | -$9.40M | -$16.63M |
| EBITDA? | -$5.65M | -$21.06M | -$39.38M | -$20.90M | -$21.75M | -$19.50M | -$12.59M | -$8.06M | -$8.24M | -$14.96M |
| Income Before Tax | -$5.69M | -$21.10M | -$39.47M | -$20.91M | -$23.88M | -$16.25M | -$12.96M | -$8.97M | -$9.24M | -$16.49M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$5.69M | -$20.66M | -$39.52M | -$20.90M | -$25.95M | -$16.25M | -$12.96M | -$8.97M | -$9.24M | -$16.49M |
| EPS? | $-0.96 | $-7.36 | $-22.14 | $-38.37 | $-386.21 | $-234.41 | $-316.76 | $-282.12 | $-317.17 | $-585.11 |
| Diluted EPS? | $-0.96 | $-7.36 | $-22.14 | $-38.37 | $-386.21 | $-234.41 | $-316.76 | $-282.12 | $-317.17 | $-585.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality